Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Edesa Biotech, Inc. - Common Shares (NQ:EDSA)

1.980 -0.090 (-4.35%)
Streaming Delayed Price Updated: 2:19 PM EDT, Oct 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Edesa Biotech, Inc. - Common Shares

< Previous 1 2 3 4 5 Next >
5 Stocks To Watch For Wednesday, December 29, 2021
5 stocks you that you should keep in mind today. 
Via Talk Markets
5 Stocks To Watch For December 29, 2021
Some of the stocks that may grab investor focus today are: Cal-Maine Foods (NASDAQ: CALM) reported weaker-than-expected earnings for its second quarter on Tuesday. Cal-Maine... 
Via Benzinga
Recap: Edesa Biotech Q4 Earnings
Edesa Biotech (NASDAQ:EDSA) reported its Q4 earnings results on Tuesday, December 28, 2021 at 04:15 PM. Here's what investors need to know about the announcement. Earnings... 
Via Benzinga
Edesa Biotech Reports Fiscal Year 2021 Results
TORONTO, ON / ACCESSWIRE / December 28, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported... 
From Edesa Biotech
Via AccessWire
Edesa Biotech Marks Enrollment Milestone in Dermatitis Study
TORONTO, ON / ACCESSWIRE / December 1, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that it... 
From Edesa Biotech
Via AccessWire
Topics Intellectual Property
How To Play Edsa Biotech's Stock After 60% Surge
Edsa Biotech Inc. (NASDAQ:EDSA) shares are trading higher ... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 20, 2021
Upgrades According to Keefe, Bruyette & Woods, the prior rating for Old National Bancorp (NASDAQ:... 
Via Benzinga
Edesa Biotech Extends COVID-19 Clinical Study to Poland
- Expansion to European Union country follows favorable Phase 2 results - Company focusing on critically ill hospitalized patients TORONTO, ON / ACCESSWIRE / November 4, 2021 / Edesa Biotech, Inc.... 
From Edesa Biotech
Via AccessWire
Topics Intellectual Property
Edesa Biotech Shares Gain As Its COVID-19 Antibody Shows Favorable Mortality Reductions
Edesa Biotech Inc (NASDAQ: EDSA) has announced additional results from the Phase 2 part of an ongoing Phase 2/3 study of EB05 as a single-dose treatment for hospitalized... 
Via Benzinga
Edesa Biotech Is Now Above Resistance: Can It Continue Higher?
Edesa Biotech Inc. (NASDAQ: EDSA) shares are trading higher Tuesday after the company announced additional results from the Phase 2 part of the ongoing Phase 2/3 study of EB05 in... 
Via Benzinga
Why Edesa Biotech Shares Are Trading Higher Today
Edesa Biotech Inc (NASDAQ: EDSA) is trading higher Tuesday after the company announced additional results from the Phase 2 part of the ongoing Phase 2/3 study of EB05 in... 
Via Benzinga
Edesa Biotech Reports Favorable Mortality Reductions in COVID-19 Study
- Mortality reductions demonstrated across multiple patient groups - Additional efficacy signals recorded in a broad range of mild to severe ARDS patients - Company to focus on critically ill... 
From Edesa Biotech
Via AccessWire
Topics Intellectual Property
50 Biggest Movers From Yesterday
Check out these big penny stock gainers and losers Losers Edesa Biotech, Inc. (NASDAQ: EDSA) shares dipped 29.9% to close at $8.36 on profit-taking after the stock... 
Via Benzinga
Mid-Afternoon Market Update: Dow Edges Lower; Helbiz Shares Spike Higher
Toward the end of trading Tuesday, the Dow traded down 0.11% to 33,932.34 while the NASDAQ rose 0.18% to 14,740.41. The S&P also fell, dropping 0.09% to 4,353.81. The U.S. has... 
Via Benzinga
Topics Stocks
Mid-Day Market Update: Gold Rises 1%; Verrica Pharmaceuticals Shares Slide
Midway through trading Tuesday, the Dow traded up 0.44% to 34,119.86 while the NASDAQ rose 0.66% to 14,810.89. The S&P also rose, gaining 0.43% to 4,376.48. The U.S. has the... 
Via Benzinga
Topics Stocks
32 Stocks Moving In Tuesday's Mid-Day Session
Gainers Helbiz, Inc. (NASDAQ: HLBZ) shares jumped 177.4% to $39.83. Helbiz Media, the media arm of Helbiz announced a deal with Amazon Italy, a unit of Amazon.com. ReWalk... 
Via Benzinga
Mid-Morning Market Update: Markets Gain; AutoZone Earnings Beat Views
Following the market opening Tuesday, the Dow traded up 0.14% to 34,017.77 while the NASDAQ rose 0.39% to 14,771.47. The S&P also rose, gaining 0.18% to 4,365.67. The U.S. has... 
Via Benzinga
Topics Earnings Stocks
The Daily Biotech Pulse: Aprea Jumps On ESMO Presentation, Verrica Sinks On Regulatory Setback, Aerie CEO Quits, J&J Touts Positive COVID-19 Booster Shot Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 20) Cerevel Therapeutics... 
Via Benzinga
18 Stocks Moving in Tuesday's Pre-Market Session
Gainers ReWalk Robotics Ltd. (NASDAQ: RWLK) rose 37% to $1.78 in pre-market trading after declining around 4% on Monday. ReWalk Robotics, last month, reported Q2 sales of $1.44... 
Via Benzinga
48 Biggest Movers From Yesterday
Gainers Edesa Biotech, Inc. (NASDAQ: EDSA) shares climbed 102.7% to settle at $11.92 on Monday after the company disclosed Phase 2 data of its monoclonal antibody in hospitalized... 
Via Benzinga
EDSA Stock: The Covid-19 News Sending Edesa Biotech Soaring on Monday
Today, the announcement of positive clinical trial results has sent investors in Edesa Biotech and EDSA stock on a nice ride. 
Via InvestorPlace
Why Edesa Biotech Shares Are Soaring Today
Edesa Biotech Inc (NASDAQ: EDSA) is surging higher Monday after the company announced positive Phase 2 data of its monoclonal antibody in hospitalized COVID-19 patients... 
Via Benzinga
Mid-Afternoon Market Update: Dow Tumbles 2.5%; BeyondSpring Shares Plunge
Toward the end of trading Monday, the Dow traded down 2.57% to 33,696.98 while the NASDAQ fell 3.14% to 14,572.25. The S&P also fell, dropping 2.58% to 4,318.67. The U.S. has... 
Via Benzinga
Topics Stocks
Edesa Biotech Stock Is Rallying After COVID-19 Antibody Data: What You Need To Know
Edesa Biotech Inc (NASDAQ: EDSA) has announced positive results from the Phase 2 part of an ongoing Phase 2/3 study evaluating EB05 as a single-dose treatment for... 
Via Benzinga
Mid-Day Market Update: Crude Oil Down 2%; Synlogic Shares Spike Higher
Midway through trading Monday, the Dow traded down 1.51% to 34,063.71 while the NASDAQ fell 2.13% to 14,723.20. The S&P also fell, dropping 1.64% to 4,360.41. The U.S. has the... 
Via Benzinga
Topics Stocks
35 Stocks Moving In Monday's Mid-Day Session
Gainers ZIVO Bioscience, Inc. (NASDAQ: ZIVO) jumped 145% to $6.86 after declining around 17% on Friday. Edesa Biotech, Inc. (NASDAQ: EDSA) jumped 30.6% to $7.68 after the company... 
Via Benzinga
Mid-Morning Market Update: Markets Open Lower; Brooks Automation Divests Semiconductor Business For $3B
Following the market opening Monday, the Dow traded down 1.42% to 34,093.46 while the NASDAQ fell 1.86% to 14,763.93. The S&P also fell, dropping 1.54% to 4,364.65. The U.S.... 
Via Benzinga
Topics Stocks
Edesa Biotech Announces Positive Phase 2 Data of Its Monoclonal Antibody in Hospitalized COVID-19 Patients
- Study unblinded due to strong efficacy signal for 28-day mortality endpoint - Critically ill patients demonstrated a 68.5% reduction in the risk of dying when treated with EB05 over Standard of Care... 
From Edesa Biotech
Via AccessWire
Topics Intellectual Property
Edesa Biotech to Present at the H.C. Wainwright Global Investment Conference
TORONTO, ON / ACCESSWIRE / September 9, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that... 
From Edesa Biotech
Via AccessWire
Topics Intellectual Property
Edesa Biotech Provides Update For COVID-19 Antibody Trial
Edesa Biotech Inc (NASDAQ: EDSA) issued an update for the Phase 2/3 study evaluating its monoclonal antibody candidate, EB05, as single-dose therapy for... 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.